Table 3. Comparison of change in cognitive outcomes over twenty years in the PAQUID cohort in subjects receiving EGb761® (n = 589) or piracetam (n = 149) compared to the ‘neither treatment’ group (n = 2874) (mixed linear effects model).

		Unadjusted for psychotropic drug use			Adjusted for psychotropic drug use
Cognitive score	Variables	β1	SE	p	β1	SE	p
Mini Mental State Evaluation	Time	−0.315	0.013	<.0001	−0.302	0.013	<.0001
	Piracetam	−0.584	0.211	0.0057	−0.592	0.202	0.0034
	EGb761®	0.482	0.089	<.0001	0.461	0.085	<.0001
Isaacs Sets Test (30 sec)	Time	−0.290	0.020	<.0001	−0.258	0.019	<.0001
	Piracetam	−1.395	0.523	0.0077	−1.468	0.516	0.0045
	EGb761®	0.213	0.231	0.3561	0.271	0.227	0.2328
Benton Visual Retention Test	Time	−0.081	0.005	<.0001	−0.078	0.004	<.0001
	Piracetam	−0.438	0.194	0.0242	−0.470	0.184	0.0106
	EGb761®	−0.030	0.085	0.7223	−0.014	0.082	0.8631

¹Covariates: age, gender, educational level, MMSE score at inclusion, depressive symptomatology and memory complaints.